Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly to Invest $3B to Expand GLP-1 Manufacturing Capacity in China  | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly to Invest $3B to Expand GLP-1 Manufacturing Capacity in China 

Investment will involve Lilly’s Suzhou facility as well as developing a network of partners to help expand production.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Lilly expands manufacturing in India

Lilly plans to invest $3 billion over the next 10 years to boost its manufacturing operations in China, according to a March 11 press release from Lilly’s Chinese operations. Lilly plans to set up local production and supply for oral solid drugs and build out capacity for orforglipron, its experimental GLP-1 pill.

Additionally, under a collaboration with Beijing-based CDMO Pharmaron, Lilly will invest $200 million to support its technology and capabilities at the CDMO to expand scale as needed.

The company has invested as much as $6 billion in its operations in China over the past two years, including several supply chain upgrades. In 2024, Lilly committed $200 million to the Suzhou site to expand the supply of its tirzepatide products, in addition to establishing research centers in the region, Eli Lilly China Medical Innovation Center and Lilly Gateway Labs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics